
|Videos|June 7, 2017
Phase I Results for Enasidenib in AML
Author(s)Eytan M. Stein, MD
Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant <em>IDH-2</em> relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.
Advertisement
Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutantIDH-2
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: Lung Cancer Advancements and FDA Decisions
2
Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma
3
Savolitinib/Osimertinib Extends PFS in MET-Amplified EGFR-Mutated NSCLC
4
Second-Line Therapy and Ruxolitinib for cGVHD
5













































